FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166351608> ?p ?o ?g. }

• W2166351608 endingPage "66" @default.
• W2166351608 startingPage "57" @default.
• W2166351608 abstract "Abstract We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human monoclonal antibody against EpCAM, in uterine serous papillary carcinoma (USPC). EpCAM expression was evaluated by real-time PCR and immunohistochemistry in a total of 56 USPC fresh-frozen biopsies and paraffin-embedded tissues. EpCAM surface expression was also evaluated by flow cytometry and immunohistochemistry in six USPC cell lines. Sensitivity to MT201 antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity was tested against a panel of primary USPC cell lines expressing different levels of EpCAM in standard 5-h 51Cr release assays. EpCAM transcript was significantly overexpressed in fresh-frozen USPC when compared with normal endometrial cells (NEC). Median (minimum–maximum) copy number was 943.8 (31.5–1568.3) in tumor samples versus 12.9 (1.0–37.0) in NEC (P &lt; 0.001). By immunohistochemistry, EpCAM expression was found in 96% (26 out of 27) of USPC samples with significantly higher expression compared with NECs (P &lt; 0.001). High surface expression of EpCAM was found in 83% (five out of six) of the USPC cell lines tested by flow cytometry. EpCAM-positive cell lines were found highly sensitive to MT201-mediated antibody-dependent cellular cytotoxicity in vitro, whereas primary USPC cell lines were resistant to natural killer cell–dependent cytotoxicity. Human plasma IgG did not significantly inhibit MT201-mediated cytotoxicity against USPC. EpCAM is highly expressed in uterine serous carcinoma at mRNA and protein levels, and primary USPC are highly sensitivity to MT201-mediated cytotoxicity. MT201 might represent a novel therapeutic strategy in patients harboring advanced/recurrent or metastatic USPC refractory to standard treatment modalities. Mol Cancer Ther; 9(1); 57–66" @default.
• W2166351608 created "2016-06-24" @default.
• W2166351608 creator A5002120924 @default.
• W2166351608 creator A5002826928 @default.
• W2166351608 creator A5007108244 @default.
• W2166351608 creator A5008166734 @default.
• W2166351608 creator A5010339370 @default.
• W2166351608 creator A5014093219 @default.
• W2166351608 creator A5024732018 @default.
• W2166351608 creator A5026827320 @default.
• W2166351608 creator A5032849063 @default.
• W2166351608 creator A5041993659 @default.
• W2166351608 creator A5045020502 @default.
• W2166351608 creator A5046857977 @default.
• W2166351608 creator A5047939895 @default.
• W2166351608 creator A5049383880 @default.
• W2166351608 creator A5061703014 @default.
• W2166351608 creator A5072462231 @default.
• W2166351608 date "2010-01-01" @default.
• W2166351608 modified "2023-09-28" @default.
• W2166351608 title "Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)" @default.
• W2166351608 cites W1678686630 @default.
• W2166351608 cites W1968244916 @default.
• W2166351608 cites W1974272943 @default.
• W2166351608 cites W1986978780 @default.
• W2166351608 cites W1987639931 @default.
• W2166351608 cites W1990795810 @default.
• W2166351608 cites W1999284510 @default.
• W2166351608 cites W2001868206 @default.
• W2166351608 cites W2016294917 @default.
• W2166351608 cites W2019897392 @default.
• W2166351608 cites W2023939059 @default.
• W2166351608 cites W2029108055 @default.
• W2166351608 cites W2029320934 @default.
• W2166351608 cites W2030467478 @default.
• W2166351608 cites W2032989773 @default.
• W2166351608 cites W2033440285 @default.
• W2166351608 cites W2037160908 @default.
• W2166351608 cites W2037817455 @default.
• W2166351608 cites W2043103956 @default.
• W2166351608 cites W2044869180 @default.
• W2166351608 cites W2065949107 @default.
• W2166351608 cites W2068441417 @default.
• W2166351608 cites W2075605944 @default.
• W2166351608 cites W2080217598 @default.
• W2166351608 cites W2095636772 @default.
• W2166351608 cites W2100117577 @default.
• W2166351608 cites W2111708038 @default.
• W2166351608 cites W2157691319 @default.
• W2166351608 cites W2165160947 @default.
• W2166351608 cites W2328201918 @default.
• W2166351608 doi "https://doi.org/10.1158/1535-7163.mct-09-0675" @default.
• W2166351608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2806489" @default.
• W2166351608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20053761" @default.
• W2166351608 hasPublicationYear "2010" @default.
• W2166351608 type Work @default.
• W2166351608 sameAs 2166351608 @default.
• W2166351608 citedByCount "35" @default.
• W2166351608 countsByYear W21663516082012 @default.
• W2166351608 countsByYear W21663516082013 @default.
• W2166351608 countsByYear W21663516082014 @default.
• W2166351608 countsByYear W21663516082016 @default.
• W2166351608 countsByYear W21663516082017 @default.
• W2166351608 countsByYear W21663516082018 @default.
• W2166351608 countsByYear W21663516082019 @default.
• W2166351608 countsByYear W21663516082020 @default.
• W2166351608 countsByYear W21663516082021 @default.
• W2166351608 countsByYear W21663516082022 @default.
• W2166351608 countsByYear W21663516082023 @default.
• W2166351608 crossrefType "journal-article" @default.
• W2166351608 hasAuthorship W2166351608A5002120924 @default.
• W2166351608 hasAuthorship W2166351608A5002826928 @default.
• W2166351608 hasAuthorship W2166351608A5007108244 @default.
• W2166351608 hasAuthorship W2166351608A5008166734 @default.
• W2166351608 hasAuthorship W2166351608A5010339370 @default.
• W2166351608 hasAuthorship W2166351608A5014093219 @default.
• W2166351608 hasAuthorship W2166351608A5024732018 @default.
• W2166351608 hasAuthorship W2166351608A5026827320 @default.
• W2166351608 hasAuthorship W2166351608A5032849063 @default.
• W2166351608 hasAuthorship W2166351608A5041993659 @default.
• W2166351608 hasAuthorship W2166351608A5045020502 @default.
• W2166351608 hasAuthorship W2166351608A5046857977 @default.
• W2166351608 hasAuthorship W2166351608A5047939895 @default.
• W2166351608 hasAuthorship W2166351608A5049383880 @default.
• W2166351608 hasAuthorship W2166351608A5061703014 @default.
• W2166351608 hasAuthorship W2166351608A5072462231 @default.
• W2166351608 hasBestOaLocation W21663516081 @default.
• W2166351608 hasConcept C109316439 @default.
• W2166351608 hasConcept C142724271 @default.
• W2166351608 hasConcept C150173356 @default.
• W2166351608 hasConcept C153911025 @default.
• W2166351608 hasConcept C159654299 @default.
• W2166351608 hasConcept C185592680 @default.
• W2166351608 hasConcept C202751555 @default.
• W2166351608 hasConcept C203014093 @default.
• W2166351608 hasConcept C204232928 @default.
• W2166351608 hasConcept C2776677690 @default.
• W2166351608 hasConcept C502942594 @default.

• next